

Applicant : John R. Neefe et al.
Serial No. : 09/891,823
Filed : June 26, 2001
Page : 2

Attorney's Docket No.: 12071-003001 / SP-21 US

8. (Reiterated) The method of claim 1, wherein the composition contains about 50 to 5000 μg of the fusion protein.
 9. (Reiterated) The method of claim 8, wherein the composition contains about 100 to 2000 μg of the fusion protein.
 10. (Reiterated) The method of claim 1, wherein the composition is administered free of adjuvant.
 11. (Reiterated) The method of claim 1, wherein the subject is a mammal.
 12. (Reiterated) The method of claim 11, wherein the mammal is a human.
 13. (Reiterated) The method of claim 1, wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.
- Add new claims 36-76.
- 36. The method of claim 1, wherein the wart is a genital wart.
 37. The method of claim 1, wherein the wart is an anogenital wart.
 38. The method of claim 1, wherein the fusion protein comprises the Hsp60 protein.
 39. The method of claim 38, wherein the Hsp60 protein is a mycobacterial hsp.
 40. The method of claim 39, wherein the mycobacterial hsp is a *Mycobacterium bovis* hsp.

Applicant : John R. Neefe et al.

Serial No. : 09/891,823

Filed : June 26, 2001

Page : 3

Attorney's Docket No.: 12071-003001 / SP-21 US

41. The method of claim 40, wherein the *Mycobacterium bovis* hsp is *Mycobacterium bovis* BCG Hsp65.

42. The method of claim 38, wherein the HPV is a type 16 HPV. *7 L. A-B-*

43. The method of claim 38, wherein the composition contains about 50 to 5000 µg of the fusion protein.

44. The method of claim 43, wherein the composition contains about 100 to 2000 µg of the fusion protein.

45. The method of claim 38, wherein the composition is administered free of adjuvant.

46. The method of claim 38, wherein the subject is a mammal.

47. The method of claim 46, wherein the mammal is a human.

48. The method of claim 38, wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.

49. The method of claim 38, wherein the wart is a genital wart. *L. P. B.*

50. The method of claim 38, wherein the wart is an anogenital wart. *77*

51. The method of claim 1, wherein the fusion protein comprises the HPV E7 protein. *9*

52. The method of claim 51, wherein the Hsp60 protein is a mycobacterial hsp. *9*

Applicant : John R. Neefe et al.
Serial No. : 09/891,823
Filed : June 26, 2001
Page : 4

Attorney's Docket No.: 12071-003001 / SP-21 US

53. The method of claim 52, wherein the mycobacterial hsp is a *Mycobacterium bovis* hsp.
54. The method of claim 53, wherein the *Mycobacterium bovis* hsp is *Mycobacterium bovis* BCG Hsp65.
55. The method of claim 51, wherein the HPV is a type 16 HPV.
56. The method of claim 51, wherein the composition contains about 50 to 5000 μg of the fusion protein.
57. The method of claim 56, wherein the composition contains about 100 to 2000 μg of the fusion protein.
58. The method of claim 51, wherein the composition is administered free of adjuvant.
59. The method of claim 51, wherein the subject is a mammal.
60. The method of claim 59, wherein the mammal is a human.
61. The method of claim 51, wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.
62. The method of claim 51, wherein the wart is a genital wart.
63. The method of claim 51, wherein the wart is an anogenital wart.
64. The method of claim 1, wherein the fusion protein comprises the Hsp60 protein and the HPV E7 protein.

Applicant : John R. Neeffe et al.
Serial No. : 09/891,823
Filed : June 26, 2001
Page : 5

Attorney's Docket No.: 12071-003001 / SP-21 US

65. The method of claim 64, wherein the Hsp60 protein is a mycobacterial hsp.
66. The method of claim 65, wherein the mycobacterial hsp is a *Mycobacterium bovis* hsp.
67. The method of claim 66, wherein the *Mycobacterium bovis* hsp is *Mycobacterium bovis* BCG Hsp65.
68. The method of claim 64, wherein the HPV is a type 16 HPV.
69. The method of claim 64, wherein the composition contains about 50 to 5000 µg of the fusion protein.
70. The method of claim 69, wherein the composition contains about 100 to 2000 µg of the fusion protein.
71. The method of claim 64, wherein the composition is administered free of adjuvant.
72. The method of claim 64, wherein the subject is a mammal.
73. The method of claim 72, wherein the mammal is a human.
74. The method of claim 64, wherein the fusion protein is administered in an amount sufficient to reduce the size of the wart.
75. The method of claim 64, wherein the wart is a genital wart.
76. The method of claim 64, wherein the wart is an anogenital wart.--

30132906.doc